Abstract
[111In-DTPA-D-Phe1]-octreotide is a new radiopharmaceutical with a great potential for the visualization of somatostatin receptor-positive tumors, granulomas, and diseases in which activated leukocytes play a role. The overall sensitivity of [111In-DTPA-D-Phe1]-octreotide scintigraphy to localize neuroendocrine tumors is high. In several neuroendocrine tumor types, inclusion of somatostatin receptor imaging in the localization or staging procedure may be very rewarding, either in terms of cost-effectiveness, patient management, or quality of life. In our opinion, this holds true for patients with carcinoids, gastrinomas, paragangliomas, small-cell lung carcinoma, and selected cases of patients with insulinomas. The value of [111In-DTPA-D-Phe1]-octreotide scintigraphy in patients with other tumors, such as breast cancer, malignant lymphomas, or in patients with granulomatous diseases, has to be established.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received 19 June 1996; Revision received 28 October 1996; Accepted 6 November 1996
Rights and permissions
About this article
Cite this article
Kwekkeboom, D., Krenning, E. Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview. Eur Radiol 7, 1103–1109 (1997). https://doi.org/10.1007/s003300050262
Published:
Issue Date:
DOI: https://doi.org/10.1007/s003300050262